nalbuphine HCl ER tablets 90 mg BID
TR03
Phase 3 small_molecule completed
Quick answer
nalbuphine HCl ER tablets 90 mg BID for Prurigo Nodularis is a Phase 3 program (small_molecule) at Trevi Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Trevi Therapeutics
- Indication
- Prurigo Nodularis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed